Synthes confirms talks with JNJ

Synthes confirms talks with JNJ

Share this story with your network

West Chester (PA), USA, April 18, 2011

 

 

In response to market speculation, Synthes, Inc. (SIX Swiss Exchange: SYST.VX), confirms that it is engaged in discussions with Johnson & Johnson about a potential business combination transaction.  No assurance can be given as to whether, when or on what terms any possible transaction might occur. Synthes does not intend to make any further public statements unless and until a definitive agreement has been reached, or until discussions between the parties have terminated.

 

Synthes: A leading medical device company
Synthes is a leading global medical device company, specialized in the development, manufacturing and marketing of instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.

 

 

Image Bank
A selection of product and company images can be found here.

For further information please contact
Gilgian Eisner, Investor Relations, Synthes, Inc.
Phone +41 32 720 47 45, Fax +41 32 720 48 11
Email: investor.relations@synthes.comhttp://www.synthes.com

 

 

Restrictions Subject to US Securities Law
Synthes, Inc. management believes certain statements in this media release may constitute “Forward-Looking Statements” within the meaning of the “Private Securities Litigation Reform Act of 1995”. These statements include but are not limited to those with respect to the potential for Synthes to offer new products and market existing ones, as well as the expected sales and sales growth of Synthes. These statements are made on the basis of management’s views and assumptions regarding future events and business performance as of the time the statements are made. Actual results may differ materially from those expressed or implied. Such differences may result from the ability of Synthes to successfully develop and introduce new products and services and market existing products and services in a competitive marketplace and changes in the economic conditions that may affect the performance of the operations of Synthes. In addition, changes in competitive conditions and regulatory developments may affect future business performance, and changing market conditions may affect the valuation of Synthes securities. In addition, it should be noted that past financial and operational performance of the company is not necessarily indicative of future financial and operational performance. Synthes undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
The securities of Synthes have been offered and sold outside the United States and have not been and will not be registered under the U.S. Securities Act of 1933, as amended (“Securities Act”). Such securities may not be offered, sold or transferred in the U.S. or to U.S. Persons (as defined in the regulations of the Securities Act), except pursuant to a registration statement filed under the Securities Act or under an applicable exemption under the Securities Act. Hedging transactions involving such securities may not be conducted unless in compliance with the Securities Act. The Synthes securities are deemed “Restricted Securities” as that term is defined in Rule 144 under the Securities Act.

 

Leave a Comment

Your email address will not be published. Required fields are marked *

*